Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Nuformix (NFX) Share News

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

Nuformix finds positive data for NXP002 in lung fibrosis study

9th Apr 2025 16:29

(Alliance News) - Nuformix PLC on Wednesday said fresh analysis of lung tissue from patients with idiopathic pulmonary fibrosis and autoimmune-related interstitial lung disease showed "positive" results for its lead asset NXP002, supporting its potential in treating a wider range of fibrotic conditions. Read More

UK shareholder meetings calendar - next 7 days

13th Mar 2025 14:41

EARNINGS AND TRADING: S-Ventures loss narrows; charge knocks Nuformix

29th Jan 2025 15:48

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Eden Research in revenue rise; Cordel gets UK deal

13th Jan 2025 12:50

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

28th Oct 2024 12:27

IN BRIEF: Nuformix shares fall despite interim loss narrowing

18th Jun 2024 18:37

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ended March 31, unchanged from a year earlier. Pretax loss narrows to GBP242,529 from GBP337,622. Read More

Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment

17th Jun 2024 10:37

(Alliance News) - Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further protections for its fibrosis and oncology technology. Read More

UK shareholder meetings calendar - next 7 days

12th Mar 2024 14:30

IN BRIEF: Nuformix announces subscription to raise GBP150,000

1st Mar 2024 10:31

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis. Read More

IN BRIEF: Nuformix narrows annual loss as develops drug assets

3rd Jan 2024 10:16

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses. Read More

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

23rd Oct 2023 12:38

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis. Read More

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

18th Sep 2023 10:20

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year. Read More

FTSE 100 Latest

Value8,772.38

Change55.93